Evalstotug is under clinical development by BioAtla and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase II drugs for Uveal Melanoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Evalstotug LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Evalstotug (BA-3071) is under development for non-small cell lung cancer, colon adenocarcinoma, small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, bladder, gastric, uveal melanoma, gastroesophageal (GE) junction carcinomas, cervical, transitional cell carcinoma (urothelial cell carcinoma) and melanoma. It acts as checkpoint inhibitor by targeting against cytotoxic T-lymphocyte antigen 4 (CTLA-4). It is based on conditionally active biologics (CAB) that optimizes antibodies to be activated and/or inactivated at defined physiological conditions.
BioAtla is a clinical-stage biopharmaceutical company that develops novel therapies for the treatment of solid tumor cancer. The company product candidate includes BA3011, BA3021 and BA3071, BA3182, BA3142, BA3311, BA336 and BA3151. BioAtla lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate (ADC) that targets AXL, which is a protein kinase receptor. Its BA3021 is developing a CAB antibody-drug conjugate directed against receptor tyrosine kinase such as orphan receptor 2 (ROR2), BA3071 is therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer and cervical cancer. BioAtla is headquartered in San Diego, California, the US.
For a complete picture of Evalstotug’s drug-specific PTSR and LoA scores, buy the report here.